Diabetic Macular Edema Market Size, Competitive Landscape and Market Forecast - 2029

Global Diabetic Macular Edema Market Is Segmented By Therapy Type (Anti-VEGF, Corticosteroids, Other Off-label Drugs), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2029

Market Overview

The Global Diabetic Macular Edema Market is expected to grow at a CAGR of 1.1% during the forecasting period (2022-2029).

• Diabetic Macular Edema (DME) is the accumulation of fluid in the macula part of the retina due to leaking blood vessels.
• DME is a major complication of diabetes and a leading cause of vision loss in persons with diabetes mellitus.
• The Global Diabetic Macular Edema market is estimated to grow to USD 4.1 billion by 2027.

Market Dynamics

• Increasing the prevalence of diabetes is the prime factor driving the growth of the Diabetic Macular Edema market.
• Globally, an estimated 422 million adults are living with diabetes.
• Besides, substantial R&D investment by pharmaceutical companies and the launch of several promising emerging therapies will fuel market growth.
• However, unfavorable reimbursement policies will restrict market growth.

Market Segmentation

• Global Diabetic Macular Edema market report segments the market by therapy type, product type, distribution channel, and region.
• Based on the therapy type, the diabetic macular edema market has been classified into anti-VEGF, corticosteroids, and other off-label drugs.
• Although laser photocoagulation therapy is being used as standard DME treatment for 25 years, the approval of anti-VEGF has revolutionized the treatment of DME.
• Based on the distribution channel, the market has been segmented into Hospital Pharmacy, Retail Pharmacy, and Others.
• Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
• North America will dominate the market owing to the high prevalence of diabetes, high awareness among people about DME, availability of treatment options, and better reimbursement policies in the region.
• In 2017, North America accounted for around 51% revenue share of the global market.

Market Competitive Analysis

• The report also profiles the following companies of the Diabetic Macular Edema market – Novartis, Roche, Allergan, Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, and Bausch & Lomb Incorporated.

By Therapy Type

• Anti-VEGF
• Corticosteroids
• Other Off-label Drugs

By Product Type

• Intravitreal Injections
• Intravitreal Implants

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region

• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
• North America (The USA, Canada, Mexico)
• South America (Brazil, Argentina, Rest of South America)
• Rest of the World

Trending Topics

Macular Edema Market

Diabetic Foot Ulcer Market

Remote Patient Monitoring Market